AP799A - Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl) phenylalkyl]-azaheterocyclylamide compounds. - Google Patents

Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl) phenylalkyl]-azaheterocyclylamide compounds. Download PDF

Info

Publication number
AP799A
AP799A APAP/P/1997/001144A AP9701144A AP799A AP 799 A AP799 A AP 799A AP 9701144 A AP9701144 A AP 9701144A AP 799 A AP799 A AP 799A
Authority
AP
ARIPO
Prior art keywords
oxopyrrolidin
aminoiminomethyl
benzyl
trifiuoroacetate
amide
Prior art date
Application number
APAP/P/1997/001144A
Other versions
AP9701144A0 (en
Inventor
William R Ewing
Michael R Becker
Yong Mi Choi-Sledeski
Heinry W Pauls
Alfred P Spada
Daniel L Cheney
Jonathan Stephen Mason
Original Assignee
Aventis Pharmaceuticals Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Products Inc filed Critical Aventis Pharmaceuticals Products Inc
Publication of AP9701144A0 publication Critical patent/AP9701144A0/en
Application granted granted Critical
Publication of AP799A publication Critical patent/AP799A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The compounds of formula (I) exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I) , compositions containing compounds of formula (I) , and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Description

SUBSTITUTED (SULFINIC ACID, SULFONIC ACID. SULFONYLAMINO OR SULFINYLAMINO) N-i(AMINOIMINOMETHYL)PHENYLALKYL)-
AZAHETEROCYCLYLAMIDE COMPOUNDS
This application is a continuation-in-part of U.S. patent application Serial No. 08/481,024, filed June 7, 1995.
Field of the Invention
The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.
Factor Xa is the penultimate enzyme in the coagulation cascade. Both free factor Xa and factor Xa assembled in the prothrombinase complex (Factor Xa, Factor Va, calcium and phospholipid) are inhibited by compounds of formula I. Factor Xa inhibition is obtained by direct complex formation between the inhibitor and the enzyme and is therefore independent of the plasma cofactor antithrombin III. Effective factor Xa inhibition is achieved by administering the compounds either by oral administration, continuous intravenous infusion, bolus intravenous administration or any other parenteral route such that it achieves the desired effect of preventing the factor Xa induced formation of thrombin from prothrombin.
Anticoagulant therapy is indicated for the treatment and prophylaxis of a variety of thrombotic conditions of both the venous and arterial vasculature. In the arterial system, abnormal thrombus formation is primarily associated with arteries of the coronary, cerebral and peripheral vasculature. The diseases associated with thrombotic occlusion of these vessels principally include acute myocardial infarction (AMI), unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy and percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication and bypass grafting of the coronary (CABG) or peripheral arteries. Chronic anticoagulant therapy may also be beneficial in preventing the vessel luminal narrowing (restenosis) that often occurs following PTCA and CABG, and in the maintenance of vascular access patency in long-term hemodialysis patients. With respect to the venous vasculature, pathologic thrombus formation frequently occurs in the veins of the lower extremities following abdominal, knee and hip surgery (deep vein thrombosis, DVT). DVT further predisposes the patient to a higher risk of pulmonary thromboembolism. A systemic, disseminated intravascular coagulopathy (DIC) commonly occurs in both vascular systems during septic shock, certain viral infections and cancer. This condition is characterized by a rapid consumption of coagulation factors and their plasma inhibitors resulting in the formation of life-threatening thrombin throughout the microvasculature of several organ systems.· The indications discussed above include some, but not all, of the possible clinical situations where anticoagulant therapy is warranted. Those experienced in this field are well aware of the circumstances requiring either acute or chronic prophylactic anticoagulant therapy.
SUMMARY OF THE INVENTION
This invention is directed to the pharmaceutical use of a compound of formula I below for treating a patient suffering from a physiological disorder capable of being modulated by inhibiting an activity of Factor Xa, where formula I is as follows:
is phenyl or monocyclic heteroaryl; R is hydrogen, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl or hydroxyalkyl;
Rn is hydrogen, R3S(O)P- or R3R4NS(O)p-;
Rj is hydrogen, or when Xs and X5. taken together are =NRS, then R2 is hydrogen, optionally substituted lower alkyl, optionally substituted aralkyl or optionally substituted heteroaralkyl; R3 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, optionally substituted aralkenyl or optionally substituted heteroaralkenyl, or R and R3 taken together form a 5 to 7 membered ring; and R4 is optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or R3 and R4 taken together with the nitrogen to which R3 and R4 are attached form an optionally substituted 4 to 7 membered heterocyclyi; X1 and X,. are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, optionally substituted heteroaralkyl or hydroxyalkyl, or X, and Xr taken together form oxo; X2 and X2. are hydrogen, or taken together form oxo; X3 is hydrogen, hydroxy, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or X3 and one of X, and Xr taken together form a 4 to 7 membered ring; X4 is hydrogen, optionally substituted alkyl, optionally substituted aralkyl, or hydroxyalkyl; X5 and Xs. are hydrogen or taken together are =NRS;
Rs is hydrogen, R6O2C-, R6O-, cyano, ReCO-, optionally substituted lower alkyl, nitro or Υ’Ύ^Ν-; Y1 and Y2’ are independently hydrogen, alkyl, aralkyl or heteroaralkyi;
Xe and X6. are independently hydrogen, R7R8N-, RgO-, R7R8NCO-, R7R8NSO2-, RgCO-, halo, cyano or nitro;
Rs is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl or optionally substituted heteroaralkyi; R7 and R8 are independently hydrogen or optionally substituted lower alkyl, or one of R7 and Rs is hydrogen and the other of R7 and Re is R10(O)CCH2- or lower . acyl;
Rg is hydrogen, optionally substituted lower alkyl, lower acyl or R10(O)CCH2-; R10 is hydrogen, optionally substituted lower alkyl, alkoxy or hydroxy; m is 0, 1,2 or 3; n is 1, 2 or 3; or p is 1 or 2, a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.
DETAILED DESCRIPTION OF THE INVENTION
As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
Definitions "Patient" includes both human and other mammals. “Alkyl" means an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups have 1 to about 12 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. “Lower alkyl“ means about 1 to about 4 carbon atoms in the chain which may be straight or branched. The alkyl may be substituted with one or more "alkyl group substituents” which may be the same or different, and include halo, cycloalkyl, alkoxy, amino, acyiamino, aroylamino, carboxy, alkoxycarbonyl, aralkyloxycarbonyl, heteroaralkyloxycarbonyl or Y1'Y2'NCO-, where Y1’ and Y2' are independently hydrogen, alkyl, aralkyl or heteroaralkyl. Exemplary alkyl groups include methyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, Apropyl, n-butyl, f-butyl, π-pentyl, 3-pentyl, methoxyethyl, carboxymethyl, methoxycarbonylethyl, benzyloxycarbonylmethyl, pyridylmethyloxycarbonyimethyl. "Cycloalkyl” means a non-aromatic mono- or multicyclic ring system of about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkyl rings include cyclopentyl, fluorocyclopentyl, cyclohexyl and cycloheptyl. The cycloalkyl group is optionally partially unsaturated or optionally substituted by one or more halo, methylene (H2C=), alkyl, fused ary or fused heteroaryl.
Exemplary multicyclic cycloalkyl rings include 1-decalin, adamant-(1- or 2-)yl and norbornyl. "Heterocyclyl” means a non-aromatic monocyclic or multicyclic ring system of about 3 to about 10 ring atoms. Preferred rings include aboui 5 to about 6 ring atoms wherein one of the ring atoms is oxygen, nitrogen or sulfur. The heterocyclyl is optionally partially unsaturated or optionally substituted by one or more alkyl, halo, aryl, heteroaryl, fused aryl or fused heteroaryl. Exemplary monocyclic rings include pyrrolidyl, piperidyl, tetrahydrofuranyl, tetrahydrothienyl and tetrahydrothiopyranyl. The thio or nitrogen moiety of the heterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. "A'ryl" means aromatic carbocyclic radical containing about 6 to about 10 carbon atoms. Exemplary aryl include phenyl or naphthyl, or phenyl substituted or naphthyl substituted with one or more aryl group substituents which may be the same or different, where "aryl group substituent" includes hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyi, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acylamino, aroylamino, alkylsuifonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyi, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaraikylthio, fused cycloalkyl, fused heterocyclyl, arylazo, heteroarylazo, Y1Y2N-, Y1Y2NCO- or Y1Y2NSO2-, where Y1 and Y2 are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyi, or Y1, Y2 and N taken together form a heterocyclyl. The aryl group substituents are as defined herein. Preferred aryl groups are optionally substituted phenyl or optionally substituted naphthyl. Preferred aryl group substituents include hydrogen, alkyl, hydroxy, acyl, aryl aroyl, aryloxy, halo, nitro, alkoxy, cyano, alkoxycarbonyl, acyiamino, alkylthio, Y1 Y2'N-, Y1 Y2'NCO- or Y1’Y2'NSO2-, where Y1' and Y2' are independently hydrogen, alkyl, aralkyl or heteroaralkyi; preferred phenyl group substituents are aryloxy and aryl; and preferred naphthyl group substituents are nitro, alkoxy and amino. "Heteroaryl” means about a 5- io about a 10- membered aromatic monocyclic or multicyclic hydrocarbon ring system in which one or more of the carbon atoms in the ring system is/are eiement(s) other than carbon, for example nitrogen, oxygen or sulfur. The "heteroaryl" may also be substituted by one or more of the above-mentioned “aryl group substituents”. Exemplary heteroaryl groups include pyrazinyl, furanyl, thienyl, pyridyl, pyrimidinyi, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimiddazolyl, benzothienyl, quinolinyl, imidazolyl and isoquinolinyl. Preferred heteroaryl groups in the R substituent include benzothienyl, thienyl, imidazolyl, pyridyl and quinolinyl all of which may be optionally substituted. Where
is monocylic heteroaryl, then preferred heteroaryls include thienyl, pyridyl and furanyl. r “Aralkyl” means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls contain a lower alkyl moiety.
Exemplary aralkyl groups include benzyl, 2-phenethyl and naphthalenemethyl. f “Heteroaralkyl” means a heteroaryl-alkyl- group in which theOieteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl moiety. Exemplary heteroaralkyl groups may contain thienyl, pyridyl, imidazolyl and pyrazinyl. “Aralkenyl” means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Preferred aralkenyls contain a lower alkenyl moiety. An exemplary aralkenyl group is 2-phenethenyl. “Heteroaralkenyl”. means a heteroaryl-alkenyl- group in which the heteroaryl and alkenyl are as previously described. Preferred heteroaralkenyls contain a lower alkenyl moiety. Exemplary heteroaralkenyl groups may contain thienyl, pyridyl, imidazolyl and pyrazinyl. “Hydroxyalkyl” means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Exemplary hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl. "Acyl" means an H-CO- or alkyl-CO- group in which the aikyl group is as previously described. Preferred acyls contain a lower alkyl. Exemplary acyl
groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, butanoyl and palmitoyl. "Aroyl" means an aryl-CO- group in which the alkyl group is as previously described. Exemplary groups include benzoyl and 1- and 2-naphthoyl. "Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, /-propoxy, n-butoxy and heptoxy. "Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Exemplary aryloxy groups include phenoxy and naphthoxy. "Aralkyloxy" means an aralkyl-O- group in which the aralkyl groups is as previously described. Exemplary aralkyloxy groups include benzyloxy and 1-or 2-naphthalenemethoxy. t "Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, /-propylthio and heptylthio. "Arylthio" means an aryl-S- group in which the aryl group is as previously described. Exemplary arylthio groups include phenylthio and naphthylthio. "Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. An exemplary aralkylthio group is benzylthio. "Y3Y4N-" means a substituted or unsubstituted amino group, wherein Y3 and Y4 are as previously described. Exemplary groups include amino (H2N-), methylamino, ethylmethylamino, dimethylamino and diethylamino. "Alkoxycarbonyl" means an alkyl-O-CO- group. Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl. "Aryloxycarbonyl" means an aryl-O-CO- group. Exemplary aryloxycarbonyl groups include phenoxy- and naphthoxycarbonyl. "Aralkoxycarbonyl" means an aralkyl-O-CO- group. An exemplary aralkoxycarbonyl group is benzyloxycarbonyl. " Y3Y4NCO-“ means a substituted or unsubstituted carbamoyl group, wherein Y3 and Y4 are as previously described. Exemplary groups are carbamoyl (H2NCO-) and dimethylaminocarbamoyl (Me2NC0-). * Y3Y4NSO2-" means a substituted or unsubstituted sulfamoyl group, wherein Y3 and Y4 are as previously described. Exemplary groups are aminosulfamoyl (H2NSO2-) and dimethylaminosulfamoyl (Me2NSC>2-). "Acyiamino'1 is an acyl-NH- group wherein acyl is as defined herein. “Aroylamino" is an aroyl-NH- group wherein aroyl is as defined herein. "Alkylsulfonyl" means an alkyl-SO2- group. Preferred groups are those in which the alkyl group is lower alkyl. "Alkylsulfinyl" means an alkyl-SO- group. Preferred groups are those in which the alkyl group is lower alkyl. "Arylsulfonyl" means an aryl-SO2- group. "Arylsulfinyl* means an aryl-SO- group. “Halo“ means fluoro, chloro, bromo, or iodo. Preferred are fluoro, chloro or bromo, and more preferred are fluoro or chloro.
Preferred Embodiments A preferred embodiment of the invention is a method for treating a patient suffering from a physiological disorder capable of being modulated by inhibiting an activity of Factor Xa by administering a therapeutically effective amount of a compound of formula I. A preferred compound aspect of the invention is the compound of formula I wherein R3 is optionally substituted phenyl, optionally substituted naphthyl, optionally substituted thienyl or optionally substituted benzothienyl.
Another preferred compound aspect of the invention is the compound of formula I wherein n is 1, and m is 1.
Another preferred compound aspect of the invention is the compound of formula I wherein X2 and X? taken together are oxo.
Another preferred compound aspect of the invention is the compound of formula I wherein Xr Xr, X3 and X4 are hydrogen.
Another preferred compound aspect of the invention is the compound of formula I wherein Xg and Xs. taken together are =NH.
Another preferred compound aspect of the invention is the compound of formula I wherein X5 and X5. taken together are =NRS wherein Rs is R6O2C-.
Another preferred compound aspect of the invention is the compound of formula l wherein
is phenyl and the carbon substituted with X5, X5. and HR2N- is attached to the 3-position of the phenyl.
Another preferred compound aspect of the invention is the compound of formula I wherein
is of the formula
Another preferred compound aspect of the invention is.the compound of formula I wherein R is hydrogen, methyl, aralkyl, heteroaralkyl, HO2CCH2-, HOC(O)CH2-, H2NC(O)CH2-, (araIkyl)HNC(O)CH2- or (heteroaralkyl)HNC(O)CH2-.
Another preferred compound aspect of the invention is the compound of formula I wherein X1 is hydrogen and Xr is carboxyalkyl, alkoxycarbonylalkyl or aryl, or X1 and Xr taken together form oxo.
Another preferred compound aspect of the invention is the compound of formula I wherein R1 is R3SO2-..
Another preferred compound aspect of the invention is the compound of formula I wherein R is R3R4NSO2-.
Another preferred compound aspect of the invention is the compound of claim 1 wherein one of X6 and X6. is amino in a para position relative to the € moiety.
Species according to the invention are selected from the group consisting of:
Naphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate;
Dibenzofuran-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-5-oxopyrrolidin-3-yl}amide trifluoroacetate;
Toluene-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 3,4-Dihydro-1H-isoquinoline-2-suifonic acid {1-[3-(aminoiminomethyl)benzyI]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate;
3’-Methoxy-biphenyl-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate;
Naphthalene-1-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Pyrid-2-ylthiophene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate;.
Biphenyl-4-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzylJ-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Ethoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyI]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-6-methoxynaphthalene-2-sulfonic acid {1-(3- (aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yI}amide trifluoroacetate; 5-Chloro-6,7-dimethoxynaphthaiene-2-sulfonic acid {1-(3- (aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifiuoroacetate; 7-Aminonaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yI}amide bistrifluoroacetate;
Naphthalene-2-sulfonic acid {1-[4-(aminoiminomethyl)benzyl]-2-oxopyrroIidin-3-(S)-yl}amide trifiuoroacetate; 7-Methoxynaphthalene-2-sulfonic acid [1-(3-aminomethylbenzyi)-2-oxopyrrolidin-3-(S)-yl]amide trifiuoroacetate;
Naphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrroiidin-3-(S)-yl}methyl amide trifiuoroacetate;
Naphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyljpyrrolidin-3-(S)-yljamide bistrifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2,5-dioxopyrrolidin-3-(S)-yi}amide trifluoroacetate;
Naphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopiperidin-3-yl}amide trifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-azepan-3-(S)-yl}amide trifluoroacetate; 7- Methoxynaphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}methyl amide trifluoroacetate; 6-Methoxynaphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 6- Methoxynaphthalene-2-sulfonic acid'{1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}methyl amide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-6- methoxynaphthalene-2-sulfonylamino]-N-phenethylacetamide trifluoroacetate; 9,10-Dioxo-8a,9,10,1Oa-tetrahydroanthracene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 8- Chloro-7-methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)-benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifiuoroacetate; 7- Methoxynaphthalene-2-sulfonic acid {1-[4-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifiuoroacetate; 6,7-Dimethoxynaphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifiuoroacetate;
Naphtho(2,3-d)-(1,3)dioxole-6-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Benzyloxynaphthalene-2-su!fonic acid {1-[3-(aminoiminomethyl)benzyl]-2· oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Hydroxynaphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 6- Hydroxynaphthalene-2-suifonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid {1-[3- (aminoiminomethyl)benzyI]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonic acid {1-[3- (aminoiminomethyl)benzyl]-2-oxopyrroIidin-3-(S)-yl}methyl amide trifluoroacetate; 7- Methylnaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 7-Ethylnaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 5-Chloro-6-aminonaphthalene-2-sulfonic acid {1-[3- (aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide bistrifluoroacetate; 7-Methylaminonaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide bistrifluoroacetate; 2-Methyl-1,2,3,4-tetrahydroisoquinolinyl-7-sulfonic acid {1-[3- (aminoiminomethyl)benzy!]-2-oxopyrrolidin-3-(S)-yl}amide bistrifluoroacetate; 1.2,3,4-Tetrahydroisoquinolinyl-7-sulfonic acid {1-[3- (aminoiminomethyl)benzyi]-2-oxopyrrolidin-3-(S)-yl}methyl amide dihydrochloride; 7-Methoxynaphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrroiidin-3-(S)-yl}-(4-nitrobenzyl)amide trifiuoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-(4-aminobenzyl)amide bistrifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}(3-nitrobenzyl)amide trifiuoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(arninoiminomethyI)benzyl]-2-oxopyrrolidin-3-(S)-yl}(3-aminobenzyl)amide bistrifluoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-(2-nitrobenzyl)amide trifiuoroacetate; 3-[2-Oxo-3(S)-(2-phenylethenesulfonylamino)pyrrolidin-1-ylmethyl]-benzamidine trifiuoroacetate; 3-[2-Oxo-3(S)-(2-phenylethanesulfonylamino)pyrrolidin-1-ylmethyl]-benzamidine trifiuoroacetate; [lmino-(3-{3-[7-Methoxynaphthalene-2-sulfonyl)methylamino]-2-oxo-3(S)-pyrrolidin-1-ylmethyl]phenyl)methyl]carbamic acid ethyl ester; 3-[2-Oxo-3(S)-{2-(pyridin-4-ylamino)-ethanesulfonylamino}-pyrrolidin-1-ylmethylj-benzamidine bistrifluoroacetate; 2’-Methoxybiphenyl-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-yl} amide trifiuoroacetate; 5,6,7,8-Tetrahydrophenanthrene-3-sutfonic acid {1-[3- (aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}amide trifiuoroacetate; lsoquinolinyl-5-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}amide bistrifluoroacetate; 5-Chlorothiophene-2-sulfonic acid {1 -[3-(arninoirninomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}amide trifiuoroacetate; 2,4-Diaminoquinazoline-6-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}amide trifiuoroacetate; 7-Methoxy-2-naphthalenesulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}ethyiamide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1 -[3-(aminoiminomethyi)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(3-fluorobenzyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(4-methylbenzyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(3-methylbenzyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyi)benzyi]-2-oxo-3(S)-pyrrolidin-3-yl}napthalene-2-ylmethylamide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrroiidin-3-yl}(3-phenylallyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(3-methylbenzyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(2-fluorobenzyl)amide trifiuoroacetate; 2- Fluorobiphenyl-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}methylamide trifiuoroacetate; 3- [{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-3-yl}-(7- methoxynaphthalene-2-sulfonyl)amino]propionamide trifiuoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}naphthalene-2-sulfonylamino]-N-phenethylacetamide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}biphenyl-4-sulfonylamino]-N-phenethylacetamide trifluoroacetate; 2-[{1-I3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthalene-2-sulfonylamino]-N-phenethylacetamide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyi)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthalene-2-sulfonylamino]-N-ethylacetamide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthalene-2-sulfonylamino]-N,N-dimethylacetamide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthalene-2-suifonylaminoJ-N-benzylacetamide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthalene-2-sulfonyiamino]-N-(2-p-toluylethyl)acetamide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthalene-2-sulfonylamino]-N-(3-phenylpropyl)acetamide trifluoroacetate; 2-[{1-l3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthaiene-2-sulfonyiamino]-N-(4-methylbenzyl)acetamide trifluoroacetate; 2-r(1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthaiene-2-sulfonyiamino]-N-[2-(3-fluorophenyl)ethyl]acetamide trifluoroacetate; 2-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrroiidin-3-(S)-yl}-7- methoxynaphthalene-2-sulfonylamino]-N-indan-2-ylacetamide trifluoroacetate; 2- [{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}-7- methoxynaphthalene-2-sulfonylamino]-N-(2-pyridin-3-yl-ethyl)acetamide bistrifluoroacetate; 4.5- Dichlorothiophene-2-sulfonic acid {1 -[3-(aminoiminomethyl)benzyi]-2-oxo-3(S)-pyrrolidin-3-yl}amide trifiuoroacetate 4.5- Dichlorothiophene -2-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrroiidin-3-yl}-methyiamide trifiuoroacetate; 4.5- Dichlorothiophene-2-sulfonic acid {1-[3-(aminoiminomethyl)benzyI]-2-oxo-3(S)-pyrrolidin-3-yl}benzylamide trifiuoroacetate; 7-Methoxy-2-napthalenesuIfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}-2-cyclopropylphenethylamide trifiuoroacetate; 3’-Methyl-biphenyl-4-sulfonic acid {1-[3-(aminoiminomethyi)benzyl]-2-oxopyrrolidin-3(S)-yl} amide trifiuoroacetate; 3- [{1-[3-(Aminoiminomethyi)benzyl]-2-oxopyrrolidin-3(S)-3-yl}-(7- methoxynaphthalene-2-sulfonyl)amino]acetamide trifiuoroacetate; 3-[{1-[3-(Aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-3-yl}-(7- methoxynaphthalene-2-sulfonyl)amino]-2-methylacetamide trifiuoroacetate; 7-Methoxynaphthalene-2-suifonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxo-azetidin-3(S)-yl}amide trifiuoroacetate; 7-Methoxynaphthalene-2-sulfonic acid {1-[3-(aminoiminorriethyl)benzyl]-2-oxo-azetidin-3(S)-yl}benzylamide trifiuoroacetate; 5,6,7,8-Tetrahydronaphthaiene-2-sulfonic acid {1-[3-(aminoiminomethyi)-benzyl]-2-oxopyrrolidin-3(S)-yl}amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}-(2-methoxybenzyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {l-[3-(aminoiminomethyi)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}-(3-methoxybenzyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesuifonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yI}-(4-methoxybenzyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyI)benzyl]-2-oxo-3(S)-pyrroiidin-3-yl}(pyridin-2-ylmethyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(pyridin-3-ylmethyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyI)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(pyridin-4-ylmethyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}-(1 -benzyl-1 H-imidazol-2-ylmethyl)amide trifiuoroacetate; (1-Methyl-1H-imidazol-2-yl)benzene-4-sulfonic acid {1-[3- (aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-yl}amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}-(3-hydroxybenzyl)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}-(2-hydroxybenzyI)amide trifiuoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(pyrazol-3-ylmethyl)amide trifiuoroacetate;
Quinoline-6-sulfonic acid {1 -[S-famino'minomethyObenzylJ^-oxopyrrolidin-S-(S)-yl}amide trifiuoroacetate; 4-Pyridin-4-ylbenzene sulfonic acid {1-[3-(aminoiminomethy!)benzyl]-2-oxopyrrolidin-3(S)-yl}amide bistrifluoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyI]-2-oxo-3(S)-pyrroiidin-3-yl}(thiophene-2-ylmethyl)amide trifluoroacetate; 4-Pyridin-3-ylbenzene sulfonic acid {1-[3-(aminoiminqmethyi)benzyl]-2-oxopyrrolidin-3(S)-yl}amide bistrifluoroacetate; N-Methylpyrid-4-ylphenyl-4-sulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-yl}amide trifluoroacetate; 2-Methoxyquinoline-7-sulfonic acid {1 -[3-(aminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}amide trifluoroacetate; 4-(6-Methoxypyridin-2-yl)benzene-4-sulfonic acid {1-[3- (aminoiminomethyl)benzyi]-2-oxopyrrolidin-3(S)-yl}amide bistrifluoroacetate; 4-(3-Chloropyridin-2-yloxy)benzene-4-sulfonic acid {1-[3- (aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-yl}amide trifluoroacetate; 4-(N-Oxidopyridin-3-yl)benzene-4-sulfonic acid {1-[3- (aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-yl}amide trifluoroacetate; 4-Phenoxybenzene-4-suifonic acid {1-[3-(aminoiminomethyl)benzyI]-2-oxopyrrolidin-3(S)-yl} amide trifluoroacetate; 7-Methoxy-2-napthalenesulfonic acid {1-[3-(aminoiminomethyl)benzyl]-2-oxo-3(S)-pyrrolidin-3-yl}(thiophen-3-ylmethyl)amide trifluoroacetate; 6-Methoxynaphthalene-2-sulfonic acid {1 -[3-(methoxyaminoiminomethyl)-benzyl]-2-oxopyrrolidin-3-(S)-yl}methylamide trifluoroacetate; 6-Methoxynaphthalene-2-sulfonic acid {1-[3-(cyanoaminoiminomethyl)benzyl]-2-oxopyrrolidin-3-(S)-yl}methyiamide trifluoroacetate; 6-Methoxynaphthaiene-2-sulfonic acid {1-[3-(hydroxyaminoiminomethyl)-benzyl]-2-oxopyrrolidin-3-(S)-yl}-methylamide trifluoroacetate; 4-Amino-3-[3-(S)-(7-methoxynaphthalene-2-sulfonyiamino)-2-oxopyrrolidin-1-yl-methyt]benzamidine dihydrochloride; 4-Amino-3-[3-(S)-(7-methoxynaphthalene-2-sulfonylrnethylamino)-2-oxopyrrolidin-1-yl-methyl]benzamidine trifiuoroacetate; N-(4-Carbamimidoyl-2-{3-[(7-methoxynaphthalene-2-sulfonyl)methylamino]-2-oxopyrrolidin-1-(S)-ylmethyl}phenyl)acetamide trifluroacetate; 4-Amino-3-[3-(S)-(4-tert-butylbenzenesulfonylamino)-2-oxopyrrolidin-1-yl- ' methyl]benzamidine trifiuoroacetate; 3- Amino-5-[3-(S)-(7-methoxynaphthalene-2-sulfonylamino)-2-oxopyrrolidin-1-yl-methyl]benzamidine bistrifluoroacetate; {4-(Aminoiminomethyl)-2-[3-(7-methoxynaphthalene-2-sulfonylamino)-2-oxopyrrolldin-1-ylmethyl]phenoxy}acetic acid methyl ester trifiuoroacetate; {4-(Aminoiminomethyl)-2-[3-(7-methoxynaphthalene-2-suifonylamino)-2-oxopyrrolidin-1-ylmethyl]phenoxy}acetic acid trifiuoroacetate; 2-Chloro-6-nitrophenoxybenzene sulfonic acid {1 -[3- (aminoiminomethyl)benzyl]-2-oxopyrrolidin-3(S)-yl}amide trifiuoroacetate; 4- [3-(S)-(7-Methoxynaphthaiene-2-sulfonylamino)-2-oxopyrrolidin-1-ylmethyl]-thiophene-2-carboxamidine trifiuoroacetate; 4-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)methylamino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 2-[[1-(5-Carbamimidoylthiophene-3-ylmethyl)-2-oxopyrrolidin-3-(S)-yl](7-methoxynaphthalene-2-sulfonyl)amino]acetamide trifiuoroacetate; 4-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)benzylamino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 4- [3-(S)-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyi]thiophene-2-carboxamidine trifiuoroacetate; 5- {3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)methylarnino]-2-oxopyrroIidin-1-ylmethyl}thiophene-3-carboxamidine trifiuoroacetate; 4-{3-(S)-[( 5-Chloro-3-methyibenzo[b]thiophene-2-sulfonyl)benzylamino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 4-{3-(S)-[(Methanesulfonyl)-(3-phenylpropyl)amino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 4-{3-(S)-[(Methanesulfonyl)(naphthalene-2-yl)amino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 4-{3-(S)-[(4,5-Dichlorothiophene-2-sulfonyl)benzylaminoJ-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 4-{3-(S)-[( 5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)methylamino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 2-[[1-(5-Carbamimidoylthiophene-3-ylmethyl)-2-oxopyrrolidin-3-(S)-yl]-(7-methoxynaphthalene-2-sulfonyl)amino]-N-phenethylacetamide trifiuoroacetate; 2-[[1-(5-Carbamimidoylthiophene-3-ylmethyl)-2-oxopyrrolidin-3-(S)-yl]-(4,5-dichlorothiophene-2-sulfonyl)amino]-N-benzylacetamide trifiuoroacetate; 2-[[1-(5-Carbamimidoylthiophene-3-ylmethyl)-2-oxopyrrolidin-3-(S)-yl]-(7-methoxynaphthalene-2-suIfonyl)amino]-N-benzylacetamide trifiuoroacetate; 2-[[1-(4-Carbamimidoylthiophene-2-ylmethyl)-2-oxopyrrolidin-3-(S)-yl]-(7-methoxynaphthalene-2-sulfonyl)amino]acetamide trifiuoroacetate; 2-[[1-(4-Carbamimidoylthiophene-2-yimethyl)-2-oxopyrrolidin-3-(S)-y!l·-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)amino]acetic acid methyl ester; 4-{3-(S)-[(7-Aminonaphthalene-2-sulfonyl)benzylamino]-2-oxopy'rolidin-1-ylmethyl}thiophene-2-carboxamidine bistrifluoroacetate; 4-{3-(S)-[(7-Aminonaphthalene-2-sulfonyl)methylamino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine bistrifluoroacetate; 2-[[1-(5-Carbamimidoylthiophene-3-ylmethyl)-2-oxopyrrolidin-3-(S)-yi]-(7-aminonaphthalene-2-sulfonyl)amino]acetamide bistrifluoroacetate; 4-[3-(S)-( 6-Amino-5-chloro-2-sulfonylamino)-2-oxopyrrolidin-1-ylmethyl]-thiophene-2-carboxamidine trifiuoroacetate; 4-{3-(S)-[(6-Amino-5-chloro-naphthalene-2-sulfonyI)methylamino]-2-oxopyrroiidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 2-[[1-(5-Carbamimidoylthiophene-3-ylmethyl)-2-oxopyrrolidin-3-(S)-yl]-(6-amino-5-chloronaphthalene-2-sulfonyl)amino]acetamide trifiuoroacetate; 4- [3-(S)-(6-Aminonaphthalene-2-sulfonylamino)-2-oxopyrrolidin-1-yimethyl]-thiophene-2-carboxamidine dihydrochloride; 5- [3-(S)-(7-Methoxynaphthalene-2-sulfonylamino)-2-oxopyrroiidin-1-ylmethyI]-thiophene-2-carboxamidine trifiuoroacetate; 5-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)methylamino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; 5-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)benzylamino]-2-oxopyrrolidin-l-ylmethyl}thiophene-2-carboxamidine trifiuoroacetate; IAmino-(4-{3-(S)-(7-methoxynaphthalene-2-sulfony!)methylamino]-2-oxopyrrolidin-1-ylmethyl}thiophene-2-yl)methylene]carbamic acid methyl e~ter trifiuoroacetate; 4-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)methylamino]-2-oxopyrrolidin-1-yimethyl}thiophene-2-N-hydroxycarboxamidine trifiuoroacetate; 4-[3-(S)-(7-Methoxynaphthalene-2-sulfonylamino)-2-oxopyrrolidin-1-ylmethyl]-pyridine-2-carboxamidine trifluoroacetate; 4-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)benzylamino]-2-oxopyrroiidin-1-ylmethyl}pyridine-2-carboxamidine trifluoroacetate; 4-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)methyiamino]-2-oxopyrroIidin-1-yimethyl}pyridine-2-carboxamidine trifluoroacetate; 4-[3-(S)-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonylamino)-2-oxopyrrolidin-1-ylmethyl]pyridine-2-carboxamidine trifluoroacetate; 4-{3-(S)-[(5-Chloro-3-methyIbenzo[b]thiophene-2-sulfonyl)methylamino]-2-oxopyrrolidin-1-ylmethyI}pyridine-2-carboxamidine trifluoroacetate; 2-{[1-(2-Carbamimidoylpyridine-4-ylmethyl)-2-oxopyrrolidin-3-(S)-yl]-(7-methoxynaphthaiene-2-sulfonyl)amino}acetamide trifluoroacetate; 2-{[1-(2-Carbamimidoyl-pyridine-4-ylmethyl)-2-oxopyrrolidin-3-(S)-yl]-(7- methoxynaphthalene-2-sulfonyl)amino}-N-phenethylacetamide trifluoroacetate; 4-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)-thiophen-3-ylmethylamino]-2-oxopyrrolidin-1-ylmethyl}pyridine-2-carboxamidine trifluoroacetate; 4-{3-(S)-[(7-Methoxynaphthalene-2-sulfonyl)thiophen-3-ylmethylamino]-2-oxopyrrolidin-1 -ylmethyl}thiophene-2-carboxamidine trifluoroacetate; 4- {3-(S)-[(4-(6-Nitro-2-chlorophenoxy)benzenesulfonyl)amino]-2-oxopyrrolidin-1 -ylmethyl}thiophene-2-carboxamidine trifluoroacetate; 5- {3-(S)-[(7-Methoxynaphthalene-2-sulfonyIamino}-2-oxopyrrolidin-1-ylmethyI}-furan-2-carboxamidine trifluoroacetate; and 4-[3-(S)-(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonylamino)-2-oxopyrrolidin-1-yimethyl]furan-2-carboxamidine trifluoroacetate.

Claims (1)

  1. Original document published without claims.
APAP/P/1997/001144A 1995-06-07 1996-06-07 Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl) phenylalkyl]-azaheterocyclylamide compounds. AP799A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/481,024 US5612353A (en) 1995-06-07 1995-06-07 Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
PCT/US1996/009816 WO1996040679A1 (en) 1995-06-07 1996-06-07 Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds

Publications (2)

Publication Number Publication Date
AP9701144A0 AP9701144A0 (en) 1998-01-31
AP799A true AP799A (en) 2000-01-19

Family

ID=23910281

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001144A AP799A (en) 1995-06-07 1996-06-07 Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl) phenylalkyl]-azaheterocyclylamide compounds.

Country Status (21)

Country Link
US (1) US5612353A (en)
EP (1) EP0853618B1 (en)
JP (1) JP4312829B2 (en)
KR (1) KR100291711B1 (en)
CN (1) CN1190395A (en)
AP (1) AP799A (en)
AT (1) ATE520655T1 (en)
AU (1) AU714319B2 (en)
BG (1) BG63628B1 (en)
BR (1) BR9608405A (en)
CA (1) CA2223403C (en)
CZ (1) CZ385397A3 (en)
EA (1) EA000700B1 (en)
HU (1) HUP9801882A3 (en)
MX (1) MX9709977A (en)
NO (1) NO310457B1 (en)
OA (1) OA10752A (en)
PL (1) PL323780A1 (en)
SI (1) SI9620093A (en)
SK (1) SK160697A3 (en)
WO (1) WO1996040679A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US5731315A (en) * 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
US5958918A (en) * 1995-06-07 1999-09-28 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compounds
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
CN1244798A (en) * 1996-12-13 2000-02-16 罗纳·布朗克罗尔药制品有限公司 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) * 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
EP0986551B1 (en) 1997-05-30 2006-08-02 Takeda Pharmaceutical Company Limited Sulfonamide derivatives, their production and use
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
DE69833036T2 (en) 1997-09-30 2006-06-22 Daiichi Pharmaceutical Co., Ltd. sulfonyl
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
CA2314401A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
UA59433C2 (en) * 1998-01-27 2003-09-15 Авентіс Фармасьютікалс Продактс Інк. Substituted oxoazaheterocyclyl inhibitors of xa factor
CN1290254A (en) 1998-02-05 2001-04-04 武田药品工业株式会社 Sulfonamide derivatives process for producing the same and utilization thereof
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
WO1999040088A1 (en) * 1998-02-09 1999-08-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
AU5196399A (en) * 1998-08-11 2000-03-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
DE19839499A1 (en) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-oxo-2H-quinoline derivatives
WO2000032590A1 (en) * 1998-11-25 2000-06-08 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
EP1150979A1 (en) * 1999-02-09 2001-11-07 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
DE19909237A1 (en) * 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-one derivatives
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
US6586617B1 (en) * 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
JP2001026506A (en) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd Sulfonamide derivative
AU5566300A (en) 1999-06-22 2001-01-09 Takeda Chemical Industries Ltd. Acylhydrazine derivatives, process for preparing the same and use thereof
EP1208097B1 (en) * 1999-07-28 2009-02-18 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
EP1317429B1 (en) 2000-09-11 2006-08-30 Genentech Inc. Amidine inhibitors of serine proteases
AU2002214266A1 (en) * 2000-11-08 2002-05-21 Takeda Chemical Industries Ltd. Carbamate derivatives, process for producing the same and use thereof
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AR032230A1 (en) * 2001-01-16 2003-10-29 Sumitomo Chem Takeda Agro Co SULFONAMIDE DERIVATIVE CONTAINING AN AGRICULTURAL AND HORTICALLY COMPOSITION
ES2274013T3 (en) 2001-01-26 2007-05-16 Schering Corporation RECEIVER ACTIVATOR (S) COMBINATIONS ACTIVATED BY THE PROOFISER OF PEROXISOMES (PPAR) AND INHIBITOR (S) M OF THE ABSORPTION OF STELORS AND TREATMENTS FOR VASCULAR DISORDERS.
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2434430A1 (en) 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
WO2002060894A2 (en) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
US6710061B2 (en) 2001-03-09 2004-03-23 Ortho-Mcneil Pharamceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
CA2440389A1 (en) 2001-03-09 2002-10-03 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
DE10112768A1 (en) * 2001-03-16 2002-09-19 Merck Patent Gmbh New heterocyclic-substituted phenyl compounds, are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, restenosis or tumor diseases
DE10139060A1 (en) 2001-08-08 2003-02-20 Merck Patent Gmbh New bicyclic benzene derivatives useful as factor Xa and VIIa inhibitors, e.g. for treating thrombosis, myocardial infarct, arteriosclerosis, inflammation, stroke, angina, restenosis and tumors
AU2002336609B2 (en) 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE10239821A1 (en) 2002-08-29 2004-03-11 Roche Diagnostics Gmbh Improvement of specificity in the determination of antithrombin
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
PT1569912E (en) 2002-12-03 2015-09-15 Pharmacyclics Llc 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
DE10302500A1 (en) 2003-01-23 2004-07-29 Merck Patent Gmbh New carboxamide derivatives useful as factor Xa or VIIa inhibitors e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation, stroke and angina
CN1756756A (en) * 2003-03-07 2006-04-05 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
AU2004249671A1 (en) 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor VIIa
WO2004113278A2 (en) 2003-05-20 2004-12-29 Genentech, Inc. Acylsulfamide inhibitors of factor viia
EP1680406A1 (en) * 2003-10-29 2006-07-19 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
EP1533298A1 (en) 2003-11-21 2005-05-25 Newron Pharmaceuticals S.p.A. 3-aminopyrrolidone derivatives
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic guanamine derivatives, as well as their products and usage
ATE517085T1 (en) * 2004-11-23 2011-08-15 Astrazeneca Ab PHENOXYACETIC ACID DERIVATIVES SUITABLE FOR THE TREATMENT OF RESPIRATORY DISEASES
AU2006244206A1 (en) 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121947A1 (en) * 1991-07-03 1993-01-07 Basf Ag 2- (3- (4-AMIDINO-PHENYL)) - PROPIONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2869092A (en) * 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
JPH05201971A (en) * 1992-01-28 1993-08-10 Hokuriku Seiyaku Co Ltd Benzenesulfonamide derivative containing cyclic amine
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
WO1995008533A1 (en) * 1993-09-21 1995-03-30 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
FR2714378B1 (en) * 1993-12-24 1996-03-15 Sanofi Sa Indol-2-one derivatives substituted in 3 with a nitrogen group, their preparation, pharmaceutical compositions containing them.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121947A1 (en) * 1991-07-03 1993-01-07 Basf Ag 2- (3- (4-AMIDINO-PHENYL)) - PROPIONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstract, vol. 119, No. 2, Col. 1, Abstract 28,018n, (MACK) *

Also Published As

Publication number Publication date
ATE520655T1 (en) 2011-09-15
NO975762L (en) 1998-02-06
CN1190395A (en) 1998-08-12
EP0853618B1 (en) 2011-08-17
HUP9801882A2 (en) 1998-12-28
EA000700B1 (en) 2000-02-28
OA10752A (en) 2001-07-04
KR100291711B1 (en) 2001-09-17
AU6166996A (en) 1996-12-30
EP0853618A4 (en) 2000-03-15
HUP9801882A3 (en) 1999-01-28
WO1996040679A1 (en) 1996-12-19
US5612353A (en) 1997-03-18
BR9608405A (en) 1999-08-24
BG63628B1 (en) 2002-07-31
EP0853618A1 (en) 1998-07-22
PL323780A1 (en) 1998-04-27
CA2223403C (en) 2002-04-23
BG102162A (en) 1998-09-30
CA2223403A1 (en) 1996-12-19
NO975762D0 (en) 1997-12-08
AP9701144A0 (en) 1998-01-31
MX9709977A (en) 1998-07-31
JP4312829B2 (en) 2009-08-12
EA199800043A1 (en) 1998-08-27
CZ385397A3 (en) 1999-05-12
SI9620093A (en) 1999-02-28
AU714319B2 (en) 2000-01-06
KR19990022386A (en) 1999-03-25
SK160697A3 (en) 1998-11-04
JPH11507368A (en) 1999-06-29
NO310457B1 (en) 2001-07-09

Similar Documents

Publication Publication Date Title
AP799A (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl) phenylalkyl]-azaheterocyclylamide compounds.
AP861A (en) Substituted N-({Aminoiminomethyl or aminomethyl} phenyl] propyl amides.
AP800A (en) Substituted sulfonic acid n-[{aminoiminomethyl)phenylalkyl] -azaheterocyclamide compounds.
AP1032A (en) Sulfonic acid or sulfonylamino n-(Heterorlkyl)-zheterocyclylmie compounds.
KR100630986B1 (en) Protease inhibitors
KR20010034442A (en) Substituted oxoazaheterocyclyl factor Xa inhibitors
WO2001039759A2 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
EP1086099A1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
SK17592002A3 (en) 4-Amino-azepan-3-one protease inhibitors, method for the preparation thereof, pharmaceutical composition comprising the same, use thereof and intermediates
US20040002487A1 (en) Protease inhibitors
US5958918A (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compounds
AU2003261482B2 (en) Protease inhibitors
HK1035489A (en) Substituted oxoazaheterocyclyl factor xa inhibitors
MXPA01006613A (en) Protease inhibitors
HK1063051A (en) 4-amino-azepan-3-one derivatives as protease inhibitors